Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-Label Extension Study of AKCEA-APOCIII-LRX (ISIS 678354) in Familial Chylomicronemia Syndrome
2021-003280-95Phase 3Active
- Sponsor
- Ionis Pharmaceuticals
- Start
- Mar 2022
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of olezarsen in primary chylomicronemia (FCS) and familial hypertriglyceridemia (FHTG), sponsored by Ionis Pharmaceuticals. Primary endpoint: Primary safety and tolerability of ISIS 678354. Started Mar 2022; status: active.
02
Drugs
olezarsen
03
Conditions
primary chylomicronemia (FCS)familial hypertriglyceridemia (FHTG)
Beyond the preview
Go deeper on 2021-003280-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003280-95.